SA Pathology delivers the vital donor screening program that has enabled Adelaide’s BiomeBank, a clinical stage biotechnology company, to become the first in the world to gain regulatory approval for a donor derived microbiome product, BIOMICTRA.
BIOMICTRA is used in Faecal Microbial Transplantation (FMT), which can effectively treat recurrent Clostridioides difficile infection, a condition which causes severe diarrhoea and is becoming more common due to the widespread use of antibiotics. Read more about how SA Pathology and BiomeBank’s innovative partnership is producing life-changing results. |